I-Chow Hsu1, Joseph P Rodgers2, Katsuto Shinohara3, James Purdy4, Jeff Michalski5, Mack Roach3, Eric Vigneault6, Robert A Ivker7, Rodger M Pryzant8, Michael Kuettel9, Daniel Taussky10, Gary S Gustafson11, Adam Raben12, Howard M Sandler13. 1. University of California, San Francisco, California. Electronic address: ichow.hsu@ucsf.edu. 2. NRG Oncology Statistics and Data Management Center. 3. University of California, San Francisco, California. 4. University of California Davis, Davis, California. 5. Washington University School of Medicine. 6. CHU de Québec Université Laval. 7. Prostate Cancer Center of New Jersey. 8. Maine Medical Center. 9. Roswell Park Cancer Institute. 10. Center Hospitalier de l'Université de Montréal-Notre Dame. 11. Beaumont CCOP. 12. Christiana Care Health System. 13. Cedars-Sinai Medical Center.
Abstract
PURPOSE: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by NRG Oncology/RTOG. METHODS AND MATERIALS: Patients with clinically localized (T1c-T3b) prostate cancer without prior history of transurethral resection of prostate or hip prosthesis were eligible for this study. All patients were treated with a combination of 45 Gy in 25 fractions from external beam radiation therapy and one HDR implant delivering 19 Gy in 2 fractions. Adverse events (AE) were collected using Common Toxicity Criteria for Adverse Events, version 3. Cumulative incidence was used to estimate time to severe late gastrointestinal (GI)/genitourinary (GU) toxicity, biochemical failure, disease-specific mortality, local failure, and distant failure. Overall survival was estimated using the Kaplan-Meier method. RESULTS: One hundred and twenty-nine patients were enrolled from July 2004 to May 2006. AE data was available for 115 patients. Patients were National Comprehensive Cancer Network (NCCN) intermediate to very high risk. The median age was 68, T1c-T2c 91%, T3a-T3b 9%, PSA ≤10 70%, PSA >10 to ≤20 30%, GS 6 10%, GS 7 72%, and GS 8 to 10 18%. Forty-three percent of patients received hormonal therapy. At a median follow-up time of 10 years, there were 6 (5%) patients with grade 3 GI and GU treatment-related AEs, and no late grade 4 to 5 GI and GU AEs. At 5 and 10 years, the rate of late grade 3 gastrointestinal and genitourinary AEs was 4% and 5%, respectively. Five- and 10-year overall survival rates were 95% and 76%. Biochemical failure rates per Phoenix definition at 5 and 10 years were 14% and 23%. The 10-year rate of disease-specific mortality was 6%. At 5 and 10 years, the rates of distant failure were 4% and 8%, respectively. The rates of local failure at 5 and 10 years were 2% at both time points. CONCLUSIONS: Combined modality treatment using HDR prostate brachytherapy leads to excellent long-term clinical outcomes in this prospective multi-institutional trial.
PURPOSE: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by NRG Oncology/RTOG. METHODS AND MATERIALS: Patients with clinically localized (T1c-T3b) prostate cancer without prior history of transurethral resection of prostate or hip prosthesis were eligible for this study. All patients were treated with a combination of 45 Gy in 25 fractions from external beam radiation therapy and one HDR implant delivering 19 Gy in 2 fractions. Adverse events (AE) were collected using Common Toxicity Criteria for Adverse Events, version 3. Cumulative incidence was used to estimate time to severe late gastrointestinal (GI)/genitourinary (GU) toxicity, biochemical failure, disease-specific mortality, local failure, and distant failure. Overall survival was estimated using the Kaplan-Meier method. RESULTS: One hundred and twenty-nine patients were enrolled from July 2004 to May 2006. AE data was available for 115 patients. Patients were National Comprehensive Cancer Network (NCCN) intermediate to very high risk. The median age was 68, T1c-T2c 91%, T3a-T3b 9%, PSA ≤10 70%, PSA >10 to ≤20 30%, GS 6 10%, GS 7 72%, and GS 8 to 10 18%. Forty-three percent of patients received hormonal therapy. At a median follow-up time of 10 years, there were 6 (5%) patients with grade 3 GI and GU treatment-related AEs, and no late grade 4 to 5 GI and GU AEs. At 5 and 10 years, the rate of late grade 3 gastrointestinal and genitourinary AEs was 4% and 5%, respectively. Five- and 10-year overall survival rates were 95% and 76%. Biochemical failure rates per Phoenix definition at 5 and 10 years were 14% and 23%. The 10-year rate of disease-specific mortality was 6%. At 5 and 10 years, the rates of distant failure were 4% and 8%, respectively. The rates of local failure at 5 and 10 years were 2% at both time points. CONCLUSIONS: Combined modality treatment using HDR prostate brachytherapy leads to excellent long-term clinical outcomes in this prospective multi-institutional trial.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: James W Denham; Chantelle Wilcox; David S Lamb; Nigel A Spry; Gillian Duchesne; Chris Atkinson; John Matthews; Sandra Turner; Lizbeth Kenny; Keen-Hun Tai; Nirdosh Kumar Gogna; Martin Ebert; Brett Delahunt; Patrick McElduff; David Joseph Journal: Radiother Oncol Date: 2012-11-03 Impact factor: 6.280
Authors: Sree Rodda; Scott Tyldesley; W James Morris; Mira Keyes; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray Journal: Int J Radiat Oncol Biol Phys Date: 2017-01-06 Impact factor: 7.038
Authors: Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler Journal: JAMA Oncol Date: 2018-06-14 Impact factor: 31.777
Authors: Gerard C Morton; D Andrew Loblaw; Raxa Sankreacha; Andrea Deabreu; Liying Zhang; Alexandre Mamedov; Patrick Cheung; Brian Keller; Cyril Danjoux; Ewa Szumacher; Gillian Thomas Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-14 Impact factor: 7.038
Authors: I-Chow Hsu; Daniel Hunt; William Straube; Jean Pouliot; Adam Cunha; Devan Krishnamurthy; Howard Sandler Journal: Pract Radiat Oncol Date: 2013-03-29
Authors: Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu Journal: J Contemp Brachytherapy Date: 2018-06-29
Authors: Jörg Tamihardja; Paul Lutyj; Johannes Kraft; Dominik Lisowski; Stefan Weick; Michael Flentje; Bülent Polat Journal: Front Oncol Date: 2021-11-26 Impact factor: 6.244
Authors: Christina Phuong; Jason W Chan; Lisa Ni; Phillip Wall; Osama Mohamad; Anthony C Wong; I-Chow Hsu; Albert J Chang Journal: Radiat Oncol Date: 2022-01-20 Impact factor: 3.481